Folotyn for Non-Hodgkin's Lymphoma Commack NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Alexander Hindenburg
(516) 663-4608
200 Old Country Rd
Mineola, NY
John W Ames
(631) 968-3636
301 E Main St
Bay Shore, NY
George Alexandru Zervos, MD
516-609-3010
333 Glen Head Rd
Glen Head, NY
Mark E Weinblatt, MD
516-663-9400
200 Old Country Rd Ste 440
Mineola, NY
Richard Li-Cheng X, MR
631-444-8382
20 Donaldson Pl
Roslyn Heights, NY
Steven Montana
(631) 751-8305
2500 Nesconset Hwy
Stony Brook, NY
Keriann Nickola Gray
(631) 261-4400
79 Middleville Rd
Northport, NY
MOHAMMAD ZARRABI, MD
(631) 444-2540
L5 University Hospital
Stony Brook, NY
Rutheelu Bayer, MD
516-922-7818
26 Glendale Dr
Oyster Bay, NY
Daphna Yael Gelblum, MD
631-623-4200
650 Commack Rd
Commack, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Commack NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Commack NY